Protocol Ledger

NCT05145127 · Phase III · RECRUITING

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Interventional Phase III clinical trial protocol NCT05145127 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-17 Enrollment: 245 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05145127
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)245 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05145127
Protocol FieldVerified Registry Value
NCT IdentifierNCT05145127
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment245 participants (ESTIMATED)
Registered Start Date2021-11-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI